Strong data shows TECNIS Odyssey Intraocular Lens (IOL) offers patients full visual range,* high contrast quality and enhanced tolerance to residual refractive error.1,2,3,4,5,6,7
Research shows higher prevalence of cataracts among Black, Hispanic and Chinese Americans, despite lower rates of cataract surgery within these groups.8
Johnson & Johnson† will give an exclusive preview of its NEW presbyopia correcting IOL, TECNIS Odyssey, at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Boston, MA, April 5-8. This cutting-edge technology is designed to provide full visual range, reduced night vision symptoms, and best-in-category contrast and low-light performance.1,9,10,11
Among 28 company-sponsored and investigator-led studies showcased at the meeting, five will focus on the real-world outcomes delivered by TECNIS Odyssey, led by surgeons with early access to the technology. TECNIS Odyssey is expected to be fully commercially available in the US during the second half of 2024.
In a series of professional educational offerings and peer-led discussions, found here, key opinion leaders who have experience implanting TECNIS Odyssey will share their experiences, insights and data gathered ahead of the full market release later this year.
“The introduction of TECNIS Odyssey marks a significant leap forward in our mission to make vision possible for more patients in the United States.” said Lori Tierney, president of Americas, Johnson & Johnson Vision.‡ “At this year's ASCRS meeting we are proud to provide Ophthalmologists a preview of our latest technology, backed by data, aimed at delivering sharp and high-quality vision for cataract patients at all distances, in all lighting conditions.”
“I had the privilege to be the first surgeon in the world to implant this IOL and since then, it has become my go to solution for high quality full range of vision and for those patients who want as much reading vision as possible.” said Elizabeth Yeu, MD, Norfolk, VA.§
Johnson & Johnson’s commitment to ophthalmology goes beyond developing groundbreaking solutions like TECNIS Odyssey. In addition to showcasing their latest innovation, data from the DEI Disparity Index Program investigating evidence-based racial, ethnic and gender-related disparities in access to cataract surgery in the U.S. will also be highlighted. Johnson & Johnson will continue the conversation in booth discussions aimed at addressing and mitigating these disparities, speaking to its bold ambition to pave the way for a new future of eye health for all: Vision Made Possible.
Key data highlights positive outcomes with TECNIS Odyssey IOL
These findings demonstrate that the newest PC-IOL provides a full range of vision, as well as high image quality and tolerance to residual refractive error as compared to existing multifocal and hybrid presbyopia correcting IOLs.1
- Electronic Poster. “Introduction of a Next Generation Presbyopia Correcting IOL.” Soscia W. Friday, April 5, 2024, 8:10 PM – 8:20 PM, BCEC. (Abstract #50695)
- Paper Presentation. “Tolerance to Refractive Error of a Next Generation Presbyopia Correcting IOL.” Al-Mohtaseb Z. Saturday, April 6, 2024, 4:15 PM – 4:20 PM, BCEC – Meeting Level 2, Room 256. (Abstract #50696)
- Paper Presentation. “Clinical Evaluation of Tolerance to Residual Refractive Errors Following Implantation with New Diffractive Presbyopia Correcting IOL.” Chang D. Saturday, April 6, 2024, 11:05 AM – 11:10 AM, BCEC – Meeting Level 2, Room 295B. (Abstract #50694)
The results suggest TECNIS Odyssey demonstrates full visual range from distance to near vision with minimal visual complaints and a high rate of being spectacle-free.1
- Paper Presentation. “Depth of Focus and Spectacle Independence 1-Month Outcomes for a New Full-Range Spectacle Independence IOL.” Waring G. Saturday, April 6, 2024, 10:40 AM – 10:45 AM, BCEC – Meeting Level 2, Room 256. (Abstract #50686)
- Paper Presentation. “Real World Evidence Visual Outcomes of a New Full-Range Spectacle-Independence Intraocular Lens.” Mathews P. Saturday, April 6, 2024, 11:15 AM – 11:20 AM, BCEC – Meeting Level 2, Room 295B. (Abstract #50685)
All educational content of the ASCRS Annual Meeting is planned by its program committee, and ASCRS does not endorse, promote, approve, or recommend the use of any products, devices, or services.According to ISO 11979-7:2024, based on the clinical study of the parent IOL.
†Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.
‡Lori Tierney is an employee of Johnson & Johnson Vision, Inc., serving as President, Americas.
§Elizabeth Yeu is an employee of Virginia Eye Consultants, as well as the President of the American Society of Cataract and Refractive Surgery.
‖Johnson & Johnson MedTech comprises the surgery, orthopedics, vision and interventional solutions businesses within Johnson & Johnson’s MedTech segment.
References
Data on File, 2024. 2024DOF4002
Mathews, P., Gounou, F., Jenkins, M., De Jesus, M., & Weeber, H. (2023). Introduction of a new next generation presbyopia correcting IOL.
Al-Mohtaseb, Z., Alarcon, A., Gounou, F., De Jesus, M., & Weeber, H. (2023). Tolerance to refractive error of a next generation presbyopia correcting IOL.
Muenz, D., De Jesus, M., Weeber, H., Vilupuru, V., & Tsai, L. (2023). Clinical evaluation of tolerance to residual refractive errors following implantation with a new diffractive presbyopia correcting IOL.
Muenz, D., De Jesus, M., & Weeber, H. (2023). Depth of focus and Spectacle independence 1-Month Outcomes for a new full-range spectacle independence IOL.
Muenz, D., De Jesus, M., Weeber, H., & Mathews, P. (2023). Real World Evidence visual outcomes of a new full-range spectacle-independence intraocular lens.
Data on File, 2023. DOF2023CT4031
Pastuck, T. (2023). Evidence-Based Disparities in Care Metrics and Outcomes Along the Continuum of Cataract Care in the United States.
Data on File, 2023. DOF2023CT4050
Data on File, 2023. DOF2023CT4051
Data on File, 2023. DOF2023CT4007